Business Wire

Tallence Selects Radisys’ Engage Platform as Foundation for New Cloud Messaging Solution

16.12.2020 16:00:00 EET | Business Wire | Press release

Share

Radisys® Corporation, a global leader of open telecom solutions, today announced that Tallence AG, a digital transformation technology and management consultancy, has selected Radisys’ Engage Media Server as the foundation for a new voice messaging system for a Tier 1 European operator. Tallence will leverage the extensive capabilities of the Engage Media Server, a foundational element of the Radisys Engage communications services enablement platform, to create enhanced digital customer experiences with high quality interactions and augment content to create greater customer satisfaction and increase customer loyalty.

Highlights

  • Digital communications solutions continue to become more integrated into both mobile and web paths of the customer journey. The COVID-19 pandemic is accelerating the shift in customer experience to online solutions. Application developers and Communication Service Providers (CSPs) must be able to quickly bring online new, scalable and elastic services that can be adapted to changing market conditions. With the right platform, they can meet the combined challenges of rapid increases and fluctuations in customer access traffic and increasingly remote, distributed workforces, all while enabling a top quality seamless experience.
  • Traditionally, only large enterprises had the infrastructure and budgets to deliver compelling digital experiences that seamlessly tie voice and video interaction with content and business processes. By migrating these services to the cloud on the foundation of Radisys’ Engage Media Server, Tallence is providing services that enable businesses of all sizes to reach their consumers at lower cost, with greater flexibility, and optimal use of resources.
  • Radisys’ Engage Media Server delivers a rich set of media capabilities for developers and CSPs to create enhanced and engaging digital customer experiences. It provides the foundation for high-value voice and video features to enrich digital experience applications, and it enables CSPs to leverage the cloud for low cost and increased efficiency with industry-leading capacities for best total cost of ownership. The cloud-based Engage Media Server delivers:
    • On demand scalability which reduces costs for broad market reach for digital experience applications and services at attractive price points.
    • Optimal user experiences that tie to brand and customer satisfaction by using high quality voice and video, including real-time processing for 4G and 5G, PSTN, and web or mobile app modalities that can adapt to various bandwidth and network conditions and ensure CSPs can meet even the most rigorous availability and quality service level agreements with their customers.
    • Powerful tools for application developers to quickly bring to market applications and services and on-demand adaptation for new campaigns through industry-leading analytics.

“Radisys’ Engage Media Server delivers the scalability and capabilities required for exceptional digital experience-related services for our new cloud-based voice messaging solution deployed for our tier-one customer,” said Christian Schöntag, Head of Consulting, Tallence AG. “Furthermore, Radisys’ extensive experience in cloud-based media processing is critical for enabling us to ensure reliability and scalability for our customers as they accelerate their move to the cloud.”

“Tallence AG has an impressive reputation in delivering innovative customer experiences that can provide compelling ROIs for their customers and sticky, loyalty building experiences for their end users,” said Al Balasco, Radisys’ Head of Media, Core and Applications Business. “Our Engage platform is deployed by over 150 operators and currently serves 2 billion users worldwide. Tallence’s cloud-based application builds on this mobile network-optimized platform to deliver services for a new age and represents the value of our media server to leading solution providers in enabling digital consumer experiences and e-commerce services.”

About Radisys

Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.

About Tallence

Tallence AG is a technology and management consultancy for digital transformation. We support our customers in using digitalization to their advantage and creating competitive advantages. We advise, develop and manage with a hands-on and result-oriented approach. Whether international technology group, traditional medium-sized enterprises or public sector: The benefit for the end customer is always the guiding principle and driving force behind Tallence. We ensure this through genuine expert performance and the highest level of commitment. Our clients come from diverse industries including telecommunications, information, media and energy. At Tallence AG more than 150 IT developers, machine learning specialists and management consultants based in our German office locations in Hamburg, Frankfurt, Marburg, Görlitz and Karlsruhe are working on future-oriented topics of the Digital Economy. Read more on: www.tallence.com.

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nereus for Radisys
Lori Mesecke, +1-503-459-9150
lmesecke@nereus-worldwide.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye